Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling ...

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...

Shares of Harrow rose after the company reaffirmed its full-year guidance for revenue between $270 million and $280 million. Shares were trading up 6.9% to $43.76 Monday morning The stock has gained ...

Harrow (HROW) shares ended the last trading session 9.7% higher at $44.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

Harrow recently experienced a 24% share price increase over the last quarter, coinciding with its announcement of a $250 million debt financing via senior unsecured notes. This announcement comes at a ...

Harrow, Inc. recently reported third-quarter 2025 results, highlighting a revenue increase to US$71.64 million and a move from a net loss to a net profit compared to the same period last year. The ...

Please provide your email address to receive an email when new articles are posted on . Harrow will inherit MELT-300, a sublingually delivered sedation product. The company plans to submit a new drug ...